Today, Pfizer's committing to offer all of their prescription medications to Medicaid, and it will be at the most favored nations. Prices is going to have a huge impact on bringing Medicaid costs down like nothing else. I told you that in my first term, I was so proud of the fact that for the first time in 28 years, drug prices came down and I had a news conference that explained it was 1/10 of 1%, but it was down.And here we're talking about, in one case, over 1,000%. This is a critical step forward to wor ...

Merck & Co., Inc. (NYSE:MRK) is included among the 10 Cash-Rich Dividend Stocks to Buy Right Now. How Merck & Co. (MRK) Turns Robust Free Cash Flow Into Shareholder Value Merck & Co., Inc. (NYSE:MRK) is an American multinational pharmaceutical company. Concerns are growing, however, as its top-selling cancer drug, Keytruda, starts losing patent protections in 2028. Since Keytruda is approximately half of Merck’s revenue, this is a potential risk. To mitigate said risks, Merck & Co., Inc. (NYSE:MRK) is d ...

收购交易概述 - 公司宣布收购位于美国亚利桑那州菲尼克斯的注射药物生产工厂 [1] - 此次特别电话会议旨在讨论该收购的战略理由和关键交易条款 [1] - 公司投资者关系网站已提供详细的演示文稿供参考 [2] 会议参与人员 - 公司投资者关系主管Marta Campos Martinez主持会议 [1] - 公司董事长兼首席执行官Juan Lopez-Belmonte参与会议 [1] - 公司副董事长兼首席财务官Javier Lopez-Belmonte参与会议 但其位于菲尼克斯且网络信号覆盖不佳 [1][2] 会议流程安排 - 会议将按照在线演示文稿内容进行 [2] - 演示结束后将设有问答环节 [2] - 参会者可在演示过程中通过平台提问按钮随时提交问题 [2]

Pfizer Inc. is set to unveil plans to lower prescription drug prices at an event on Tuesday alongside President Donald Trump, according to multiple White House officials, as per a report. The announcement will include measures aimed at making medicines more affordable for Americans, particularly those enrolled in the Medicaid program, Bloomberg reported.Pfizer is expected to implement broad reductions in US drug prices, with Medicaid patients receiving “most favored nation” pricing on select medicines, the ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Indivior PLC is one of them. Indivior PLC (NASDAQ:INDV) is a pharmaceutical company specializing in treatments for opioid use disorder (OUD), with its core products SUBLOCADE, a once-monthly buprenorphine injection, and SUBOXONE film forming the backbone of its revenue. In September 2025, the corporation reported strong Q2 results, with total net revenue of $302 million. SUBLOCADE sales rose 9% year-over-year to $20 ...

The planned 230,000 square-foot plant is the healthcare company's latest step in a 10-year plan to modernize and expand its distribution network. ...

For many years, Americans have paid the highest prices anywhere in the world for prescription drugs. They paid far more, 10 times, 13 times, 15 times more than other countries for the exact same product. A major reason is that the American consumers have been subsidizing research and development costs for the entire planet.They put all of that on us and yet they were the beneficiaries to. So, it's being changed as of today. The United States had just 4% of the world's population and consumers, only 13% of a ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America's role as the global leader in biopharmaceutical innovation. In response to the four points covered in the President's July 31st letter, Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in o. ...

Welcome to Market Catalyst. I'm Julie Hyman. We are 30 minutes into the US trading day. Let's get to the three market catalysts we're watching this hour. First up, the clock is ticking for the government to stay open or shut down. We're going to break down the economic implications of a shutdown. Plus, consumer confidence data crossing the wire. We'll have details ahead and interpretation. And Nike is set to report earnings after the bell. We'll get a read on its turnaround and look at the broader winners a ...

PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATEST Paris, September 30 2025, 6.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its financial report for the first half of 2025, initially scheduled for 30 September 2025, to give the auditors time to complete their audit work. The Company will ...